FSHR rs121912529: Reproductive Health and Variant Insights
The genetic variant rs121912529 is an ultra-rare missense change located in the follicle-stimulating hormone receptor (FSHR) gene. It causes a loss of function in the FSH receptor, disrupting normal ovarian response to pituitary hormone signaling. In medical literature, homozygous or compound heterozygous inheritance of this variant is associated with hypergonadotropic hypogonadism, primary ovarian insufficiency, and ovarian dysgenesis.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| Reference / Reference (Homozygous Normal) | You carry two normal copies of the FSHR gene at this position. Your cells produce fully functional follicle-stimulating hormone receptors, conferring standard baseline receptor activity without elevated genetic risk for FSHR-linked ovarian dysgenesis. | Favorable |
| Reference / Alternate (Heterozygous Carrier) | You carry one functional allele and one loss-of-function allele. Because this condition is inherited in an autosomal recessive manner, carriers typically produce enough normal receptors to preserve regular reproductive and endocrine function. | Informational |
| Alternate / Alternate (Homozygous Variant) | You carry two copies of the loss-of-function variant, significantly impairing FSH receptor signaling. In clinical research, this genotype is strongly linked to hypergonadotropic hypogonadism, primary amenorrhea, and ovarian dysgenesis. | Higher attention |
What Is rs121912529 and Where Is It Located?
The variant rs121912529 represents a single-nucleotide alteration within the FSHR gene, located on chromosome 2. This variant introduces an amino acid substitution—historically documented in foundational endocrine genetics as an alanine-to-valine change (p.Ala189Val)—within the extracellular ligand-binding domain of the receptor. Under standard nomenclature, the reference allele encodes the functional receptor, whereas the alternate allele disrupts standard protein folding and transport to the cell surface. Because the cellular machinery fails to properly express the receptor at the plasma membrane, target tissues become largely unresponsive to circulating follicle-stimulating hormone. Unlike common non-coding polymorphisms, rs121912529 directly alters the primary structure of the protein, categorizing it as a classic loss-of-function missense mutation.
The Biological Role of the FSHR Gene
The FSHR gene provides instructions for producing the follicle-stimulating hormone receptor, a member of the G-protein coupled receptor family. In females, this receptor is predominantly expressed on ovarian granulosa cells, where it binds follicle-stimulating hormone (FSH) released by the anterior pituitary. Normal binding stimulates intracellular cyclic AMP (cAMP) production, initiating downstream cascades such as the PI3K-AKT and ERK signaling pathways. These signals govern ovarian follicle maturation, estrogen synthesis, and normal menstrual cycling. In males, the receptor is expressed in testicular Sertoli cells, where it contributes to the regulation of spermatogenesis. When receptor signaling is impaired or absent, gonadal development and gametogenesis stall despite elevated pituitary gonadotropin release.
Clinical Significance and Evidence Strength
The clinical evidence linking rs121912529 to hypergonadotropic hypogonadism and ovarian dysgenesis type 1 is classified as moderate to strong in established endocrine literature. Originally identified in Finnish families presenting with primary amenorrhea and underdeveloped secondary sexual characteristics, this variant follows an autosomal recessive inheritance pattern. Individuals carrying two loss-of-function alleles typically present with elevated serum FSH and luteinizing hormone (LH) paired with deficient estrogen, a condition often described as resistant ovary syndrome or hypergonadotropic hypogonadism. While phenotypic expression can occasionally vary, heterozygous carriers generally possess adequate wild-type receptor activity to maintain normal reproductive physiology and fertility.
Population Frequency and Genetic Distribution
According to broad population databases such as gnomAD and ClinVar, rs121912529 is an ultra-rare variant globally. It is virtually absent from most international reference panels, with documented occurrences largely traced to specific founder effects in Northern European cohorts, particularly in Finland. Because pathogenic loss-of-function alleles in the FSHR gene are exceedingly uncommon, the vast majority of people carry two copies of the reference allele. Identifying a homozygote or compound heterozygote in general population screening is an extraordinary event, with the variant almost exclusively recognized through targeted diagnostic evaluation for primary ovarian insufficiency or hereditary hypogonadism.
Interpreting Results and Practical Next Steps
Encountering rs121912529 on a personal genetic report requires careful contextualization. Genetic testing platforms can occasionally produce false positives for ultra-rare variants; thus, any unexpected finding should be clinically validated via Sanger sequencing or an accredited clinical diagnostic panel. It is critical to recognize that carrier status (heterozygosity) does not equal a diagnosis of ovarian insufficiency or infertility. Genetic data alone should never be used to initiate, alter, or discontinue hormone replacement or fertility medications. Individuals with questions regarding their reproductive health, hormone profiles, or genetic carrier screening should review their results with a board-certified medical geneticist or reproductive endocrinologist.
How common is this variant?
The rs121912529 variant is an ultra-rare pathogenic allele across worldwide populations in gnomAD, observed primarily at very low frequencies in specific cohorts with Finnish ancestry due to a founder effect.
Frequently asked questions
What health conditions are associated with rs121912529?
Homozygous or compound heterozygous carriage of rs121912529 is associated with hypergonadotropic hypogonadism, primary ovarian insufficiency, and ovarian dysgenesis type 1. These conditions are characterized by poorly developed ovaries, absence of menses, and elevated pituitary hormone levels.
Does having one copy of this variant cause infertility?
Generally, no. Because FSHR-related ovarian dysgenesis follows an autosomal recessive pattern, heterozygous carriers retain one functional copy of the gene, which typically produces sufficient receptor activity for normal puberty and fertility.
How common is rs121912529 in the general population?
This variant is exceptionally rare globally, often classified as ultra-rare. While historically identified within Finnish pedigrees due to a genetic founder effect, it is seldom seen in broad multi-ancestry population databases.
Can medical treatments overcome an FSHR receptor defect?
Because the underlying receptor cannot properly respond to follicle-stimulating hormone, standard ovarian stimulation protocols using FSH are usually ineffective in affected homozygotes. Management typically focuses on hormone replacement therapy to support secondary sexual characteristics and bone density, guided by an endocrinologist.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121912529?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29